Physician profile
Janet Johnson
NPI 1245861442
$1,026.30
in general payments reported to CMS, 2019-2025
14 companies · $359 in 2025
The $359 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $287 · 2024: $381 · 2025: $359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,026.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,026.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $371.57 | 2023-2025 | |
| Pfizer INC. | $293.32 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $81.32 | 2023-2024 | Nuplazid |
| E.R. Squibb & Sons, L.L.C. | $42.99 | 2023 | Zeposia |
| Ucb, INC. | $38.31 | 2023-2024 | Briviact |
| Celgene Corporation | $35.12 | 2023-2024 | Zeposia |
| Amgen INC. | $31.38 | 2024 | Uplizna |
| Jazz Pharmaceuticals INC. | $30.24 | 2023-2024 | |
| Horizon Therapeutics Plc | $22.50 | 2023 | Uplizna |
| Teva Pharmaceuticals USA, INC. | $17.27 | 2023 | Austedo Xr |
| Neurocrine Biosciences, INC. | $15.94 | 2024 | Ingrezza |
| Axsome Therapeutics, INC. | $15.81 | 2025 | Symbravo |
| Argenx US, INC. | $15.51 | 2023 | Vyvgart |
| Csl Behring | $15.02 | 2024 | Hizentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.